Rxsight, Inc. (RXST)
NASDAQ:RXST
Want to see RXST full AI Analyst Report?
RXST Stock Chart & Stats
$7.61
-$1.16(-3.26%)
At close: 4:00 PM EST
$7.61
-$1.16(-3.26%)
Day’s Range― - ―
52-Week Range$5.30 - $16.48
Previous CloseN/A
Volume110.15K
Average Volume (3M)687.99K
Market Cap
$251.90M
Enterprise Value$245.15M
Total Cash (Recent Filing)$217.88M
Total Debt (Recent Filing)$10.83M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 10, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding41,396,610
10 Day Avg. Volume578,722
30 Day Avg. Volume687,991
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)1.56
Price to Sales (P/S)3.19
P/FCF Ratio-22.18
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue1.92
Enterprise Value/Gross Profit2.50
Enterprise Value/Ebitda-4.89
Forecast
1Y Price Target
$9.83Price Target Upside29.22% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-1.4
Revenue Forecast (FY)$129.25M
Bulls Say, Bears Say
Bulls Say
Installed Base GrowthMeaningful expansion of the installed base increases the addressable market and provides a foundation for recurring procedure volume and follow-on revenue as adoption scales.
Management ExpertiseAppointment of an experienced finance executive as CFO brings senior medical device finance expertise, which can strengthen financial oversight and investor confidence during the company’s operational transition.
Product DifferentiationAdjustable intraocular lens that can be modified after implantation allows surgeons to fine-tune patient vision outcomes, creating a differentiated product that supports premium positioning and continued adoption.
Bears Say
Adoption Hurdles For SurgeonsAdditional post-operative visits and increased procedural work required for the adjustable lens make it harder for surgeon offices to adopt the product, slowing sales ramp among newly trained surgeons.
Cost And Margin PressureLower production volumes are creating higher per-unit manufacturing costs and expected gross margin pressure, which could constrain profitability until volumes recover.
Macroeconomic And Pricing RiskMacroeconomic headwinds may reduce uptake of premium products and weaken pricing power, limiting revenue growth potential in more price-sensitive segments.
RxSight News
RXST FAQ
What was Rxsight, Inc.’s price range in the past 12 months?
Rxsight, Inc. lowest stock price was $5.30 and its highest was $16.48 in the past 12 months.
What is Rxsight, Inc.’s market cap?
Rxsight, Inc.’s market cap is $251.90M.
When is Rxsight, Inc.’s upcoming earnings report date?
Rxsight, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 76 days.
How were Rxsight, Inc.’s earnings last quarter?
Rxsight, Inc. released its earnings results on May 06, 2026. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.299 by -$0.081.
Is Rxsight, Inc. overvalued?
According to Wall Street analysts Rxsight, Inc.’s price is currently Undervalued.
Does Rxsight, Inc. pay dividends?
Rxsight, Inc. does not currently pay dividends.
What is Rxsight, Inc.’s EPS estimate?
Rxsight, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Rxsight, Inc. have?
Rxsight, Inc. has 41,396,610 shares outstanding.
What happened to Rxsight, Inc.’s price movement after its last earnings report?
Rxsight, Inc. reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.299. Following the earnings report the stock price went down -14.454%.
Which hedge fund is a major shareholder of Rxsight, Inc.?
Currently, no hedge funds are holding shares in RXST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RxSight Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.83 (29.22% Upside)
$9.83 (29.22% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 148.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 10.4%
Last 30 Days ▼ 10.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.70%
12-Months-Change
Fundamentals
Return on Equity
-17.01%
Trailing 12-Months
Asset Growth
-2.89%
Trailing 12-Months
Company Description
Rxsight, Inc.
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
RXST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: operational positives include stabilized LAL procedure volumes, improved gross margin in Q1, a major commercial milestone (300,000 implants), early signs of success from customer reengagement programs, and maintained full-year revenue guidance. Offsetting these are sizable near-term challenges — an 18% YoY revenue decline, weak LDD capital placements (only 20 sold), a Q1 net loss of $15.9M, increased SG&A/OpEx investments, and anticipated margin pressure from higher-cost inventory that will weigh on near-term profitability. Management projects gradual sequential improvement and is investing to drive longer-term growth, but near-term financial headwinds and modest 2026 volume expectations temper the outlook.View all RXST earnings summariesRXST Stock 12 Month Forecast
Average Price Target
$9.83
▲(29.22% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Butterfly Network
―
NeuroPace
―
Ceribell, Inc.
―
Ownership Overview
5.57% Insiders
14.08% Mutual Funds
23.90% Other Institutional Investors
42.46% Public Companies and
Individual Investors